Shares of Edwards Lifesciences Corporation (EW) traded 1.77 points or 1.84% higher at $98.01.The total intraday money flow for the shares came in at a disappointing $(-4.47) million. The total upticks amounted to $56.1 million and the total downticks were approximately $60.57 million, with the up/down ratio of 0.93. On a different note, the shares have seen 0.73% price change during the week.In a block trade which occurred during the day, the stock had an inflow of $4.13 million in upticks and an outflow of $1.96 million in downticks. The up/down ratio for the block was found to be 2.11. The net money flow for the block transaction was $(2.17) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Edwards Lifesciences Corporation rose by 2.05% in the last five trading days and 4.61% for the last 4 weeks. Edwards Lifesciences Corporation is up 2.94% in the last 3-month period. Year-to-Date the stock performance stands at 4.61%. Edwards Lifesciences Corporation (NYSE:EW) rose 1.85% or 1.78 points on Wednesday and made its way into the gainers of the day. After trading began at $96.51 the stock was seen hitting $98.38 as a peak level and $96.11 as the lowest level. The stock ended up at $98.02. The daily volume was measured at 3,191,315 shares. The 52-week high of the share price is $121.75 and the 52-week low is $75.29. The company has a market cap of $21,233 million.
Company has reported several Insider transactions to the SEC, on Jan 17, 2017, Michael A Mussallem (Chairman & CEO) sold 49,100 shares at 97.03 per share price.On Jan 17, 2017, Donald E Jr Bobo (CVP, Heart Valve Therapy) sold 13,720 shares at 97.42 per share price.On Dec 6, 2016, Huimin Wang (CVP, Japan & Intercontinental) sold 13,650 shares at 83.54 per share price.
Edwards Lifesciences Corp Last issued its quarterly earnings results on Feb 1, 2017. The company reported $0.75 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $0.72. The company had revenue of $767.70 million for the quarter, compared to analysts expectations of $758.54 million. The companys revenue was up 14.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Edwards Lifesciences Corp was Upgraded by Guggenheim to Buy on Jan 3, 2017.
Edwards Lifesciences Corporation provides products and technologies to treat late-stage cardiovascular disease. The Companys products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences Corporation is headquartered in Irvine, California.